Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:14:09.024Z.
Calculation as of: 2026-10-06T22:14:09.024Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 62e543f524ee8633d6080f2a553f9cbd6b945788c6a084cb4464cef9d8d253d7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$7.07M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exicure, Inc. (XCUR) | $6.88M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.04M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.15M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.61M | N/A | 1.29% | 1.35% | 1.32% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.60M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | N/A | 3.10% | 3.10% | 1.95% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
